![]() | Andrew Alan NIERENBERGDepartment of Psychiatry, Harvard Medical School | Harvard Medical School, Boston, Massachusetts | Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA. | ... |
KOL Resume for Andrew Alan NIERENBERG
Year | |
---|---|
2022 | Department of Psychiatry, Harvard Medical School Dauten Family Center for Bipolar Treatment Innovation, Massachusetts General Hospital, Boston |
2021 | Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02115, USA Dauten Family Center for Bipolar Treatment Innovation, Massachusetts General Hospital |
2020 | Bipolar Clinical and Research Program, Massachusetts General Hospital, Boston, MA, USA Department of Affective Disorders, Aarhus University Hospital ‐ Psychiatry, Aarhus, Denmark Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, United States |
2019 | Massachusetts General Hospital and Harvard Medical School, Boston CHANG: Women’s Treatment Program, McLean Hospital, Belmont, MA |
2018 | Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts Instituto de Informatica, Universidade Federal de Goias, Goiania, GO, Brazil |
2017 | Department of Psychiatry Harvard Medical School Boston MAUSA Harvard Medical School, 25 Shattuck Street, 02115, Boston, MA, USA |
2016 | Department of Psychiatry and Depression Clinical and Research Program, Harvard Medical School and Massachusetts General Hospital, Boston, MA, USA Massachusetts General Hospital, Boston, MA, United States |
Andrew Alan NIERENBERG: Influence Statistics
Concept | World rank |
---|---|
cvlt hippocampus | #1 |
duloxetinetreated patients escitalopram | #1 |
ketamine lurasidone | #1 |
naa bipolar subjects | #1 |
1 099 women | #1 |
galantamine‐er | #1 |
introduction sgas | #1 |
pregnancy delivery offspring | #1 |
nextstep interventions | #1 |
asrs attentional difficulties | #1 |
variables antidepressants | #1 |
generic hazard ratio | #1 |
specific mood symptoms | #1 |
remission psychotic features | #1 |
bipolar depression participants | #1 |
aroc symptom remission | #1 |
work performance individuals | #1 |
treatment outcomes lithium | #1 |
lower rates generic | #1 |
anthropometric measures behavior | #1 |
spending treatment adherence | #1 |
lithium apts | #1 |
indications medication adjustment | #1 |
worsened depression | #1 |
primary objective onset | #1 |
generic risperidone spending | #1 |
exercise new tx | #1 |
mthfr gene treatment | #1 |
bipolar disorder treatment | #1 |
behaviors emotional expression | #1 |
action track progress | #1 |
relapse remitters | #1 |
quetiapine depressive episodes | #1 |
episode polarity measures | #1 |
illness characteristics women | #1 |
analysis alcohol abuse | #1 |
mood disorders moodnetwork | #1 |
psychosocial interventions comorbid | #1 |
msitiaps | #1 |
lmethylfolate tolerability | #1 |
thase rush | #1 |
higher rates remission | #1 |
frequent exercise mania | #1 |
adjustment clinical inertia | #1 |
onset criteria week | #1 |
absenteeism occupations | #1 |
anxiety bipolar disorder | #1 |
hamd6 unidimensional measure | #1 |
associations offspring psychopathology | #1 |
remitters pharmacotherapy | #1 |
Open the FULL List in Excel | |
Prominent publications by Andrew Alan NIERENBERG
OBJECTIVE: The goal of a non-inferiority study is to test whether a new treatment has at least as much efficacy as an established treatment. The purpose of this non-inferiority study was to compare the speed of onset of antidepressant efficacy for duloxetine (a dual serotonin and norepinephrine reuptake inhibitor) and escitalopram (a selective serotonin reuptake inhibitor).
RESEARCH DESIGN AND METHODS: This was a randomized, double-blind, placebo- and active comparator-controlled study, ...
Known for Duloxetine Escitalopram | Depressive Disorder | 8 Weeks | Antidepressant Action | Placebo Treatment |
Residual symptoms after remission of major depressive disorder with fluoxetine and risk of relapse
[ PUBLICATION ]
BACKGROUND: Many patients with major depressive disorder (MDD) who achieve full remission after antidepressant treatment still have residual depressive symptoms. In this study, we assess the type and frequency of residual symptoms and their relationship to subsequent depressive relapses after remission of major depression with fluoxetine.
METHOD: Five hundred seventy-six patients with MDD were openly treated with fluoxetine for 12 weeks. Those who responded underwent random assignment, ...
Known for Residual Symptoms | Major Depressive Disorder | Patients Remission | Acute Phase | Risk Relapse |
Bipolar disorders are a complex group of severe and chronic disorders that includes bipolar I disorder, defined by the presence of a syndromal, manic episode, and bipolar II disorder, defined by the presence of a syndromal, hypomanic episode and a major depressive episode. Bipolar disorders substantially reduce psychosocial functioning and are associated with a loss of approximately 10-20 potential years of life. The mortality gap between populations with bipolar disorders and the ...
Known for Bipolar Disorders | Childhood Maltreatment | Depressive Disorder | Cardiovascular Disease | Psychosocial Functioning |
Psychopathology in the offspring of parents with bipolar disorder: a controlled study.
[ PUBLICATION ]
BACKGROUND: To examine the risk for psychopathology in offspring at risk for bipolar disorder and the course of psychiatric disorders in these youth.
METHODS: Using structured diagnostic interviews (Structured Clinical Interview for DSM-IV [SCID] and Kiddie Schedule for Affective Disorders and Schizophrenia [K-SADS]), psychiatric diagnoses of 117 nonreferred offspring of parents with diagnosed bipolar disorder were compared with those of 171 age- and gender-matched offspring of parents ...
Known for Bipolar Disorder | Offspring Parents | Controlled Study | Risk Psychopathology | Major Depression |
OBJECTIVE: Bipolar disorder is highly comorbid with substance use disorders, and this comorbidity may be associated with a more severe course of illness, but the impact of comorbid substance abuse on recovery from major depressive episodes in these patients has not been adequately examined. The authors hypothesized that comorbid drug and alcohol use disorders would be associated with longer time to recovery in patients with bipolar disorder.
METHOD: Subjects (N=3,750) with bipolar I or ...
Known for Bipolar Disorder | Time Recovery | Systematic Treatment | Enhancement Program | Substance Comorbidity |
BACKGROUND: Systematic studies of children and adolescents with a diagnosis of bipolar disorder show that rates of attention-deficit/hyperactivity disorder (ADHD) range from 60% to 90%, but the prevalence and implications of ADHD in adults with bipolar disorder are less clear.
METHODS: The first consecutive 1000 adults with bipolar disorder enrolled in the National Institute of Mental Health's Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) were assessed for ...
Known for Bipolar Disorder | Comorbid Adhd | Lifetime Prevalence | Attention Deficit | Systematic Studies |
OBJECTIVE: Little is known about clinical features associated with the risk of recurrence in patients with bipolar disorder receiving treatment according to contemporary practice guidelines. The authors looked for the features associated with risk of recurrence.
METHOD: The authors examined prospective data from a cohort of patients with bipolar disorder participating in the multicenter Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) study for up to 24 months. For ...
Known for Bipolar Disorder | Risk Recurrence | Depressive Episode | Shorter Time | Systematic Treatment |
Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report
[ PUBLICATION ]
BACKGROUND: Many patients with major depressive disorder (MDD) who experience full symptomatic remission after antidepressant treatment still have residual depressive symptoms. We describe the types and frequency of residual depressive symptoms and their relationship to subsequent depressive relapse after treatment with citalopram in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial.
METHOD: Participants in primary (n=18) and psychiatric (n=23) practice settings ...
Known for Residual Symptoms | Major Depressive Disorder | Risk Relapse | Treatment Citalopram | Patients Remission |
BACKGROUND: After unsuccessful treatment for depression with a selective serotonin-reuptake inhibitor (SSRI), it is not known whether switching to one antidepressant is more effective than switching to another.
METHODS: We randomly assigned 727 adult outpatients with a nonpsychotic major depressive disorder who had no remission of symptoms or could not tolerate the SSRI citalopram to receive one of the following drugs for up to 14 weeks: sustained-release bupropion (239 patients) at a ...
Known for Sustainedrelease Bupropion | Remission Symptoms | Depression Hrsd17 | Extendedrelease Venlafaxine | Ssri Antidepressant |
Do Comorbid Anxiety Disorders Moderate the Effects of Psychotherapy for Bipolar Disorder? Results From STEP-BD
[ PUBLICATION ]
OBJECTIVE: At least 50% of individuals with bipolar disorder have a lifetime anxiety disorder. Individuals with both bipolar disorder and a co-occurring anxiety disorder experience longer illness duration, greater illness severity, and poorer treatment response. The study explored whether comorbid lifetime anxiety in bipolar patients moderates psychotherapy treatment outcome.
METHOD: In the Systematic Treatment Enhancement Program randomized controlled trial of psychotherapy for bipolar ...
Known for Bipolar Disorder | Comorbid Anxiety | Intensive Psychotherapy | Patients Lifetime | Greater Illness Severity |
BACKGROUND: Although clinicians frequently add a second medication to an initial, ineffective antidepressant drug, no randomized controlled trial has compared the efficacy of this approach.
METHODS: We randomly assigned 565 adult outpatients who had nonpsychotic major depressive disorder without remission despite a mean of 11.9 weeks of citalopram therapy (mean final dose, 55 mg per day) to receive sustained-release bupropion (at a dose of up to 400 mg per day) as augmentation and 286 to ...
Known for Medication Augmentation | Sustainedrelease Bupropion | Remission Symptoms | Greater Reduction | Citalopram Therapy |
Key People For Bipolar Disorder
Andrew Alan NIERENBERG:Expert Impact
Concepts for whichAndrew Alan NIERENBERGhas direct influence:Bipolar disorder, Major depressive disorder, Bipolar depression, Depressive disorder, Suicidal ideation, Major depression, Major depressive, Mood disorders.
Andrew Alan NIERENBERG:KOL impact
Concepts related to the work of other authors for whichfor which Andrew Alan NIERENBERG has influence:Bipolar disorder, Depressive symptoms, Major depression, Suicidal ideation, Mental health, Antidepressant treatment, Depressed patients.
Tools
Is this your profile? Claim your profile Copy URL Embed Link to your profile |